Am J Transplant, Volume 5, Suppl 3 Archives - Page 63 of 170 - ATC Abstracts

2015 American Transplant Congress
The Clinical Outcome of Plasma Cell-Rich Rejection of Kidney Allograft
J. Hasegawa,¹ K. Honda,² S. Wakai,¹ H. Shirakawa,³ M. Okumi,³ K. Omoto,³ H. Ishida,³ K. Tanabe.³
¹Nephrology, Ohkubo Hospital, Tokyo, Japan; ²Pathology, Tokyo Women's Medical University, Tokyo, Japan; ³Urology, Tokyo Women's Medical University, Tokyo, Japan.
Background: Plasma cell-rich rejection (PCRR) is a rare type of allograft rejection characterized by the presence of mature plasma cells. This type of rejection has…
2015 American Transplant Congress
SBRT(Stereotactic Body Radiotherapy) to Bridge or Down-Size HCC for Liver Transplantation
N. Thai,¹ K. Tom,¹ M. Szramowski,¹ P. Abrams,¹ J. Oliva,³ D. Monga,⁴ M. Raj,⁴ D. Parda,² A. Kirichenko.²
¹Transplant Surgery, Allegheny Health Network, Pittsburgh, PA; ²Radiation Oncology, Allegheny Health Network, Pittsburgh, PA; ³Hepatology, Allegheny Health Network, Pittsburgh, PA; ⁴Medical Oncology, Allegheny Health Network, Pittsburgh, PA.
Twenty seven (27) pts with HCC and cirrhosis have been treated with SBRT with intent for liver transplantation since 2010 at Allegheny Health Network. Nineteen…
2015 American Transplant Congress
Severe Sarcopenia and Increased Fat Stores in Pediatric Patients With Liver, Kidney and Intestine Failure
W. Bush, C. Miller, C. Kubal, J. Fridell, A. Tector, R. Mangus.
Transplant Division, Dept of Surgery, Indiana University School of Medicine, Indianapolis, IN.
Background: Recent research suggests that measures of frailty, such as nutrition status, may be important predictors of surgical and transplant outcomes. The objectively calculated degree…
2015 American Transplant Congress
Pubertal Development in Pediatric Kidney Transplant Patients Receiving Everolimus Or Conventional Immunosuppression
L. Pape,¹ T. Ahlenstiel-Grunow,¹ A. Zapf,² M. Mynarek,³ J. Förster.¹
¹Pediatric Nephrology, Hannover Medical School, Hannover, NDS, Germany; ²Medical Statistics, University Medical Center Göttingen, Göttingen, NDS, Germany; ³Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
TOR inhibitors (mTORi) have been discussed to eventually influence pubertal development after pediatric kidney transplantation (Tx).This is the first trial to compare pubertal development in…
2015 American Transplant Congress
Cancer Mortality Among Recipients of Solid Organ Transplant in Ontario
S. Acuna,^1,2,3 K. Fernandes,⁴ C. Daly,^2,3 L. Hicks,³ R. Sutradhar,^1,4 S. Kim,^1,4 N. Baxter.^1,2,3,4
¹Institute of Health Policy, Management and Education, University of Toronto, Toronto, ON, Canada; ²Department of Surgery, St. Michael's Hospital, Toronto, ON, Canada; ³Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada; ⁴Institute for Clinical Evaluative Sciences, Toronto, ON, Canada.
Purpose: Solid organ transplantation recipients (SOTR) have a higher risk of some cancers than the general population, but are also at high risk of mortality…
2015 American Transplant Congress
Kidney Transplantation After Hematopoietic Cell Transplantation in Plasma Cell Dyscrasias
V. Domínguez-Pimentel,¹ F. Fortich-Barrios,¹ O. Siverio-Morales,¹ E. Martín-Izquierdo,¹ A. Jarque-López,¹ N. Del Castillo-Rodríguez,¹ J. García,¹ P. Ríos,² M. Macía.¹
¹Division of Nephrology, Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain; ²Division of Hematology, Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain.
INTRODUCTION:The plasma cell dyscrasias (PCD) include a number of entities such as multiple myeloma (MM), primary amyloidosis (AL) and Monoclonal immunoglobulin deposition disease (MIDD). Hematopoietic…
2015 American Transplant Congress
Favorable Long-Term Outcome of Late-Onset CMV Disease in D+R- Kidney Transplant Recipients Treated With Universal Prophylaxis
H. Kaminski,¹ L. Couzi,^1,2 I. Garrigue,^3,4 J. Déchanet-Merville,² P. Merville.^1,2
¹Nephrologie-Transplantation-Dialyse, CHU Bordeaux, Bordeaux, France; ²Unité Mixte de Recherche 5164, Centre National de la Recherche Scientifique, Bordeaux, France; ³Laboratoire de Virologie, CHU Bordeaux, Bordeaux, France; ⁴Unité Mixte de Recherche 5234, Centre National de la Recherche Scientifique, Bordeaux, France.
Based on last international guidelines, both universal prophylaxis and preemptive strategies are viable approaches for the prevention of cytomegalovirus (CMV) disease after organ transplantation. Universal…
2015 American Transplant Congress
Changing Demographics of HIV+ Liver Transplant Candidates
C. Durand, S. Gustafson, J. Locke, J. Snyder, B. Shelton, R. Reed, P. MacLennan, S. Mehta, A. Nellore, D. Segev.
Johns Hopkins University, Baltimore, MD; Scientific Registry of Transplant Recipients (SRTR), Minneapolis Medical Research Foundation, Minneapolis, MN; University of Alabama, Birmingham, Birmingham, AL.
Liver transplant (LT) is considered a reasonable therapeutic option for certain HIV+ patients with end-stage liver disease (ESLD). As OPTN does not collect HIV status…
2015 American Transplant Congress
HLA Broad Antigen and Eplet Mismatches in Determining the Risk of Acute Rejection After Kidney Transplantation
H. Do Nguyen,¹ W. Lim,^1,2 J. Chapman,³ J. Craig,^3,4 G. Wong.^3,4
¹School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia, Australia; ²Renal Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia; ³Nephrology, The Children's Hospital at Westmead, Sydney, New South Wales, Australia; ⁴School of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Aim: To determine the clinical relevance of HLA-ABDR broad antigen and eplet matching for predicting acute rejection after kidney transplantation.Background: HLAMatchmaker determines structurally HLA compatibility…
2015 American Transplant Congress
Immune Reconstitution in Recipients of Living Donor Kidney/Hematopoietic Stem + Facilitating Cell Transplants
J. Leventhal,¹ M. Elliott,² E. Yolcu,² L. Bozulic,³ D. Tollerud,³ J. Mathew,¹ I. Konieczna,¹ M. Ison,¹ M. Badder,³ M. Abecassis,¹ J. Miller,¹ L. Gallon,¹ S. Ildstad.³
¹Comprehensive Transplant Center, Northwestern Memorial Hospital, Chicago, IL; ²University of Louisville, Institute for Cellular Therapeutics, Louisville, KY; ³Regenerex, LLC, Louisville, KY.
We report the long-term results from a reduced-intensity nonmyeloablative conditioning approach to establish high levels of donor chimerism without graft-versus-host disease (GVHD) in mismatched related…